Business Context and Reporting Period
This Form 8-K is a current report filed by Coeptis Therapeutics Holdings, Inc. (the registrant) on April 28, 2026, regarding events occurring on April 27, 2026. The filing addresses a business combination between Z Squared, Inc. (NASDAQ: ZSQR) and Coeptis Therapeutics Holdings, Inc. It also covers a pro rata dividend distribution related to Coeptis's pre-business combination biopharmaceutical business.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of corporate events rather than a financial performance report.
Material Changes
- Business Combination: Z Squared, Inc. announced a business combination with Coeptis Therapeutics Holdings, Inc.
- Dividend Distribution: A pro rata dividend distribution was issued related to Coeptis's pre-business combination biopharmaceutical business.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) for detailed information regarding the business combination and dividend distribution. No specific forward-looking guidance, management commentary on future performance, or detailed risk factors are included in the text of this Form 8-K summary.
Investor Verification Checklist
- Verify the terms of the business combination between Z Squared, Inc. and Coeptis Therapeutics Holdings, Inc. in the attached press release.
- Confirm the amount and timing of the pro rata dividend distribution related to the biopharmaceutical business.
- Review the impact of the transaction on the capital structure of both entities.
- Check for any subsequent filings detailing the financial implications of the merger.